Bromantane

Bromantane (also known in the literature as Ladasten) is a synthetic adamantane derivative developed at the Zakusov Institute of Pharmacology in the 1980s. It belongs to the actoprotector class — compounds studied for enhancing resistance to physical and mental load without the metabolic cost of classical stimulants. It is lipophilic, crosses the blood-brain barrier readily, and published human pharmacokinetic data report a half-life of roughly 11 hours. Its long research history spans work-capacity studies, asthenia trials in the Russian clinical literature, and mechanistic work on dopamine synthesis.

Bromantane's research interest comes from its mechanism. Classical stimulants raise synaptic dopamine by blocking reuptake or forcing release — borrowing against existing stores. Bromantane instead upregulates the expression of tyrosine hydroxylase and aromatic L-amino acid decarboxylase, the enzymes that determine how much dopamine the brain can synthesize. One frequently cited study measured a 65% increase in tyrosine hydroxylase activity within four hours of administration, with elevation persisting beyond 24 hours. The literature also describes a distinctive dual profile: mild psychostimulation paired with anxiolytic effects, without the sedation that usually accompanies anxiety-reducing compounds.

Few research compounds carry bromantane's pedigree. It was studied in a 700-subject multicenter clinical trial for asthenia in the Russian literature, and it entered Western awareness in 1996 when it was added to the World Anti-Doping Agency's prohibited list after detections at the Atlanta Olympics — a historical marker of how seriously its work-capacity effects were taken. Real Peptides supplies bromantane as 100mg capsules, 100 per bottle, with independent third-party testing published for the exact batch you receive.